EIR Biopharma
ApprovedOur therapeutic development efforts center on targeting the Ephrin receptor for the treatment of neurodegenerative disease, proliferative neovascular disease and cancer. Our initial therapeutic focus is the treatment of certain eye diseases by modulation of Ephrin receptor dysregulation.
Founded
2019
Focus
OncologyImmunology
About
Our therapeutic development efforts center on targeting the Ephrin receptor for the treatment of neurodegenerative disease, proliferative neovascular disease and cancer. Our initial therapeutic focus is the treatment of certain eye diseases by modulation of Ephrin receptor dysregulation.
Company Info
TypePrivate
Founded2019
LocationSan Diego, United States
StageApproved
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile